Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute Myeloid Leukemia

Amanda F. Cashen, Gary J. Schiller, Margaret R. O'Donnell, John F. DiPersio

Research output: Contribution to journalArticlepeer-review

396 Scopus citations


Purpose: Older patients with acute myeloid leukemia (AML) have limited treatment options because of the lack of effectiveness and the toxicity of available therapies. We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML. Patients and Methods: In this multicenter, phase II study, patients older than 60 years who had AML (ie, > 20% bone marrow blasts) and no prior therapy for AML were treated with decitabine 20 mg/m2 intravenously for 5 consecutive days of a 4-week cycle. Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subsequent cycle. Patients continued to receive decitabine until disease progression or an unacceptable adverse event occurred. Results: Fifty-five patients (mean age, 74 years) were enrolled and were treated with a median of three cycles (range, one to 25 cycles) of decitabine. The expert-reviewed overall response rate was 25% (complete response rate, 24%). The response rate was consistent across subgroups, including in patients with poor-risk cytogenetics and in those with a history of myelodysplastic syndrome. The overall median survival was 7.7 months, and the 30-day mortality rate was 7%. The most common toxicities were myelosuppression, febrile neutropenia, and fatigue. Conclusion: Decitabine given in a low-dose, 5-day regimen has activity as upfront therapy in older patients with AML, and it has acceptable toxicity and 30-day mortality.

Original languageEnglish
Pages (from-to)556-561
Number of pages6
JournalJournal of Clinical Oncology
Issue number4
StatePublished - Feb 1 2010


Dive into the research topics of 'Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this